Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 18 of 18 publications.
Skip to main content
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Chen L, Xiong Y, Yan C, Zhou W, Endo Y, Xue H, Hu Y, Hu L, Leng X, Liu J, Lin Z, Mi B, Liu G. LncRNA KCNQ1OT1 accelerates fracture healing via modulating miR-701-3p/FGFR3 axis. FASEB J. 2020 Apr;34(4):5208-22. doi: 10.1096/fj.201901864RR
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Saande CJ, Reed CH, Coonts CA, Hahn KE, Rowling MJ, Schalinske KL. Vitamin D derived from dietary whole egg is more effective than supplemental vitamin D3 in maintaining vitamin D balance in type 2 diabetic rats. Poster presented at the Experimental Biology 2017 Meeting; April 2017. [abstract] FASEB J. 2018 Oct 3; 31(S1):436.1. doi: 10.1096/fasebj.31.1_supplement.436.1
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Saande CJ, Schalinske KL, Rowling MJ. Whole egg consumption attenuates vitamin D insufficiency in type 1 diabetic rats. Poster presented at the Experimental Biology 2016 Meeting; April 2016. [abstract] FASEB J. 2016 Apr 1; 30(S1):917.8. doi: 10.1096/fasebj.30.1_supplement.917.8
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor–positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010 Sep 1;15(9):944-53.
Sherrill EH, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15(9):944-53.
Arab L, Jardack P, Anthony MS, Schoeller DA. Validity and feasibility of self administered multiple web-based 24 hour recalls: diet day. FASEB J. 2008.
Arab L, Anthony MS, McKenzie DC, Hartline HL, Prentice E. Web-based multimedia dietary assessment tool for nutritional research. FASEB J. 2002;16 (5 Pt 1):A383.
Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Cholesterol efflux potential of serum from atherogenic diet-fed cynomolgus monkeys after long-term tibolone treatment or traditional hormone replacement therapy. FASEB J. 2001;15(4):A248.
Cline JM, Anthony MS, Register TC, Borgerink H, Clarkson TB. Tibolone does not stimulate the endometrium or breast in cynomolgus monkeys. FASEB J. 2001;15(4):A594.
Shadoan MK, Rankin SE, Anthony MS, Clarkson TB, Wagner JD. Tibolone increases lean mass and bone mineral density in cynomolgus monkeys. FASEB J. 2001;15(4):A595.
Anthony MS, Pan Y-L, Hughes C, Bullock B, Clarkson TB. Hybrid hamsters as a model for estrogen effects on brain biomarkers. FASEB J. 1997 Feb;11:A107.
Brosnihan KB, Weddle D, Anthony MS, Heise CM, Ferrario CM. Chronic estrogen or estrogen and progestin replacement on the renin-angiotensin system in ovariectomized cynomolgus monkeys. FASEB J. 1995;9:A51.